Pfizer Stock Has 29% Upside, Says a New Bull

Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.

Related Keywords

,Emily Dattilo ,Pfizer ,Courtesy Pfizer ,Vamil Divan ,Dow Jones Market ,Wall Street ,Article Normal ,Pharmaceuticals ,Vaccines ,Textiles ,Wholesalers ,Retail Wholesale ,Healthcare Life Sciences ,Clothing Textiles ,Consumer Goods ,Specialized Drugs Medications ,Financial Performance ,Earnings ,Earnings Surprises ,Analysts Amp 39 Comments Recommendations ,Corporate Industrial News ,Political General News ,Respiratory Tract Diseases ,Health ,Immunizations ,Medical Conditions ,Novel Coronaviruses ,Infectious Diseases ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Street Notes ,Biotech And Pharma ,Healthcare ,Moderna ,Mrna ,Pfe ,S Amp Ampp 500 Index ,Spx ,Analysts Amp 39 Comments ,Recommendations ,Corporate ,Industrial News ,Political ,General News ,Medical Treatments ,Procedures ,Retail ,Wholesale ,Life Sciences ,Clothing ,Specialized Drugs ,Medications ,